Analysis of FDA reports reveals widespread ocular adverse events linked to antidepressants
A pharmacovigilance analysis of FDA adverse event reports identified more than 62,000 ocular adverse event reports linked to antidepressant use. Norepinephrine-dopamine disinhibitors (NDDIs) and selective serotonin reuptake inhibitors (SSRIs) showed the strongest associations with eye-related complications. The analysis, which included data from the FDA Adverse Event Reporting System (FAERS), noted 62,020 ocular adverse event reports... ...
